Parinam advised and represented a large phamaceutical company before the Competition Commission of India (CCI) in an inquiry initiated by the Director General (DG) of the CCI, concerning allegations of anti-competitive conduct involving purported marketing agreements among competitors aimed at controlling the pricing of oral anti-diabetic drugs, and examining the nature of the relationships among the parties involved.
